CN1197614C - Chinese medicine cap sule for treating prostatic disorders - Google Patents
Chinese medicine cap sule for treating prostatic disorders Download PDFInfo
- Publication number
- CN1197614C CN1197614C CN 03155282 CN03155282A CN1197614C CN 1197614 C CN1197614 C CN 1197614C CN 03155282 CN03155282 CN 03155282 CN 03155282 A CN03155282 A CN 03155282A CN 1197614 C CN1197614 C CN 1197614C
- Authority
- CN
- China
- Prior art keywords
- grams
- group
- stranguria
- radix
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a Chinese medicine capsule for treating prostate diseases, which belongs to the field of Chinese medicines. Prostatitis, prostate hyperplasia, prostatic hyperplasia and urinary tract infection are usual and frequent diseases in clinical operation. In Chinese medicine, prostate diseases are called stranguria, turbid urine and uroschesis. At present, Chinese patent medicines for treating prostate diseases are Qianliekang, Qianlie Tongyu capsules, Longbishu capsules, etc.; the Chinese patent medicines have certain curative effect but has the defects that the effect is not obvious enough and the cure rate is lower. The present invention provides a Chinese medicine capsule (Linzhuoqing capsule) for treating prostate diseases. The main raw materials of the Chinese medicine capsule are 13 pure Chinese medicines of glabrous greenbrier rhizome, yam rhizome, yellow-corktree bark, spreading hedyotis herb, largehead atractylodesrhizome, ginseng, earth worm, common cnidium fruit, etc. The present invention has the functions of promoting urination, treating stranguria, activating blood circulation for removing blood stasis, clearing heat-toxin, benefiting Qi and tonifying the kidney; the present invention enhances curative effect and also has the effects of life extension and aging resistance.
Description
Technical field:
The present invention relates to a kind of medicine for the treatment of prostatitis, prostatic hyperplasia hypertrophy, urinary tract infection disease, is the Chinese patent medicine of feedstock production with the Chinese crude drug specifically, belongs to the field of Chinese medicines.
Background technology:
Prostatitis, prostatic hyperplasia, prostate hyperplasia and urinary tract infection, it is clinical common frdquently encountered disease, especially middle-older patient has a strong impact on patient's physical and mental health and quality of life because of prostatic hyperplasia or that loose smooth, the urine thin of urinating, oliguria, the urine that causes is waited for, urine is unable etc. is painful unusual.The traditional Chinese medical science claims that prostatosis is " stranguria ", " turbid urine ", " difficulty in urination ".
Theory of Chinese medical science is thought: stranguria ", diseases such as " turbid urine ", " difficulty in urination "; how because of the pungent delicious food savoury of surfeit; or be addicted to drink too; or cloudy down unclean, foul heresy invade bladder, make give birth to damp and hot, damp and hot not understanding and in accumulate, make a bet in bladder, damp and hot fumigation, disturbance in functioning of QI; or because of heat accumulate in lung, lung qi can not respectfully fall, the defeated cloth of body fluid is not normal, the logical accent of water channel is unfavorable, can not descend defeated bladder; or because of feelings will is hindered, depression of liver-QI, catharsis are unfavorable, or because of stagnated QI transforming into fire, all can influence the operation gasification function of three warmers water liquid, cause the logical accent of water channel to be obstructed; Or with age, eipathia asthenia and overwork, intemperate sexual intercourse, insufficiency of kidney-YANG, decline of the fire from the gate of life, QI failing to transform into body fluid, ' depletion of YANG is being difficult of the moon then ", or because of the part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels is not healed long-pending summerday for a long time, body fluid consume so that kidney yin loss, the exhaustion of water mansion; Or because of overstrain impairing the spleen, eating and drinking without temperance, or eipathia asthenia, cause insufficiency of the spleen and clear QI failing to ascend, turbid YIN failing to descend; Or cause forming because of life, the resistance of the urinary tract stasis of blood etc. in obstinate disease, the blood stasis.Symptom shows as: adularescent mucus is overflowed on the urethra, especially with after the stool; Frequent micturition, to drench drop not smooth, and hypogastric region, perineum or scrotum portion pain are seen hematuria sometimes, and severe patient is with sexual impotence, premature ejaculation, hemospermia, seminal emission and malaise, Mental fatigue etc.
At present, the Chinese patent medicine of treatment prostatosis has QIANLIEKANG, qian lie tong yu jiao nang, Longbishu Jiaonang. etc., though these Chinese patent medicines all have certain curative effect, effect is remarkable inadequately, cure rate is lower.
Summary of the invention:
The object of the present invention is to provide a kind of Chinese medicinal capsule (stranguria with turbid discharge clearing capsule) for the treatment of prostatosis, have that dampness removing is treating stranguria, an effect of blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, vital energy benefiting and the kidney invigorating, not only improved therapeutic effect, also have life lengthening, antidotal effect.
It is right that solution of the present invention is based on motherland's medical science: " stranguria ", " turbid urine ", " difficulty in urination " cause of disease, sick position, pathological knowledge: main at bladder, but closely related with three warmers, lung, spleen, liver, kidney; With the damp-heat accumulation part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels, functioning of bladder unfavorable for seeing more, but hold concurrently stasis of blood resistance, the deficiency of vital energy, pathological change such as suffer from a deficiency of the kidney more.Follow the Therapeutic Principle of " method is upright from demonstrate,proving, and Fang Congfa goes out ", be based on clearing away heat-damp and promoting diuresis, assistant is established the principle of treatment of, blood circulation promoting and blood stasis dispelling treating stranguria with dampness removing, heat-clearing and toxic substances removing, vital energy benefiting and the kidney invigorating with treating stranguria, promoting blood circulation to remove obstruction in the collateral, vital energy benefiting and the kidney invigorating, can reach the effect for the treatment of both the principal and secondary aspects of a disease with this.
The present invention by traditional Chinese medical science monarch, minister, help, make the principles of formulating prescriptions, with ' Rhizoma Smilacis Glabrae ', ' Bi ' clearing away heat-damp and promoting diuresis, separating clear and excreting turbid are monarch, minister is with ' Cortex Phellodendri ', ' Herba Hedyotidis Diffusae ' principal drug assistance clearing away heat-damp and promoting diuresis, detoxifcation, assistant makes with ' Pheretima ' heat clearing away collateral dredging diuretic eliminating stagnation, ' Radix Cyathulae ' restores menstrual flow and invigorates blood circulation, ' Rhizoma Acori Graminei ' sensible eliminating phlegm, the pain relieving of ' Radix Linderae ' regulating the flow of QI to alleviate depression, ' Radix Ginseng ' QI invigorating is set upright, ' Rhizoma Atractylodis Macrocephalae ' spleen reinforcing and in, ' Fructus Alpiniae Oxyphyllae ' solid and gas benefit is smart, ' Fructus Cnidii ' warming the kidney to activate YANG, ' Radix Glycyrrhizae uralensis ' gone in the stem to drive away stranguria with turbid discharge and lost essence, and sick spontaneous recovery.The monarch compatibility, all medicines share, and the dampness removing that gathers altogether is treating stranguria, the merit of blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, vital energy benefiting and the kidney invigorating.In addition, described medicine: ' Rhizoma Smilacis Glabrae ', ' Bi ', ' Cortex Phellodendri ' have tangible antibacterial and anti-inflammation functions, ' Herba Hedyotidis Diffusae ', ' Radix Cyathulae ', ' Pheretima ' can effectively suppress proliferation of fibrous tissue, microcirculation improvement, ' Bi ', ' Fructus Cnidii ' have diuresis, and ' Radix Ginseng ', ' Rhizoma Atractylodis Macrocephalae ' can improve body's immunological function.Therefore, can not only improve or eliminate urinary tract infection effectively, the pathological change of prostatitis, the loose disease of prostatic hyperplasia improves therapeutic effect widely, but also has life lengthening, antidotal effect.
The present invention is according to its main disease to be treated, effect and dosage form, with medicine called after " stranguria with turbid discharge clearing capsule ".
The weight proportion of medicine material of the present invention is: Rhizoma Smilacis Glabrae 30 grams, Cortex Phellodendri 10 grams, the Radix Linderae 10 grams, Fructus Alpiniae Oxyphyllae 10 grams, the Rhizoma Atractylodis Macrocephalae 10 grams, Bi 15 grams, Radix Cyathulae 10 grams, Radix Ginseng 8 grams, Herba Hedyotidis Diffusae 30 grams, Pheretima 10 grams, Rhizoma Acori Graminei 10 grams, Radix Glycyrrhizae uralensis 6 grams, Fructus Cnidii 10 grams.
The step of the compound method of medicine of the present invention is as follows:
(1) Rhizoma Smilacis Glabrae by weight ratio, Cortex Phellodendri, the Radix Linderae, Fructus Alpiniae Oxyphyllae, the Rhizoma Atractylodis Macrocephalae, Bi , Radix Cyathulae, Herba Hedyotidis Diffusae, Pheretima, Rhizoma Acori Graminei, Radix Glycyrrhizae uralensis, Fructus Cnidii 12 flavor Chinese medicines are soaked;
(2) decoct secondary;
(3) collecting decoction, filtration;
(4) filtrate to be concentrated into relative density be 1.35-1.40;
(5) Chinese medicine Radix Ginseng powder essence by weight ratio, sieve;
(6) with concentrated thick paste and the mixing of Radix Ginseng fine powder such as above-mentioned Rhizoma Smilacis Glabraes;
(7) drying;
(8) pulverize, sieve;
(9) branch is encapsulated.
The present invention is owing to selected medicine with obvious antibacterial and anti-inflammation functions for use and can effectively suppress proliferation of fibrous tissue, microcirculation improvement, diuresis and medicine that can the human body immunity improving function are arranged, the pharmacological action of these medicines, can improve or eliminate the pathological change of diseases such as urinary tract infection, prostatitis, prostatic hyperplasia hypertrophy effectively, therefore, the present invention have that dampness removing is treating stranguria, the function of blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, vital energy benefiting and the kidney invigorating.Be used for the treatment of urinate not smooth, dripping not to the utmost, Urethra astringent pain or frequent micturition, urine thin, urine wait, impotence and premature ejaculation, renal function diseases such as prostatitis, prostatic hyperplasia hypertrophy, urinary tract infection such as go down, not only improve therapeutic effect, but also had life lengthening, antidotal effect.
The specific embodiment:
Below further set forth the beneficial effect of medicine of the present invention by testing example, these are tested pharmacodynamics test, toxicity test and the clinical observation on the therapeutic effect that examples have comprised medicine of the present invention (to call the stranguria with turbid discharge clearing capsule in the following text) and test.
Test example 1: the main pharmacodynamics experiment of stranguria with turbid discharge clearing capsule
One, test material
1, be subjected to the reagent thing:
(1) stranguria with turbid discharge clearing capsule, the suitable crude drug of every gram 5.55 grams, solvent is a distilled water, it is standby to be mixed with 4.2%, 8.4% suspension.
(2) Longbishu Jiaonang., Kedi Pharmaceutical Co., Ltd., Shijiazhuang produces, and lot number 001002 is made 10% suspension.
(3) androlin (TP) injection, Shanghai the 9th pharmaceutical factory produces, lot number 00120211.
2, animal:
Kunming kind white mice, the Wistar rat.
Two, test method
1, to the influence of mouse experiment prostatic hyperplasia
1.1 preventive effect: get 50 of body weight 25g mices, be divided into the normal control group at random, the prostatic hyperplasia model group, the big small dose group of stranguria with turbid discharge clearing capsule, the Longbishu Jiaonang. group, every group 10, each administration group mice ig every day administration, while Sc androlin (TP) 0.005g/kgd, normal control group body such as ig and Sc is simultaneously knitted normal saline (20ml/kg body weight), continuous 21 days, put to death mice in the 22nd day, cut open and get prostate and weigh, calculate prostate index (the heavy mg/ body weight of prostate g), and the prostate of winning is done specimens paraffin embedding slices, observe morphological changes of various tissue components.
1.2 therapeutical effect: get 60 of body weight 25g mices, 45 Sc TP 0.005g/kg.d wherein, 15 normal control group Sc give the equal-volume normal saline, get 5 of Sc TP mices after 21 days at random, 5 execution of normal control mice, cut open inspection and confirm prostate hypertrophy, confirm the modeling success, at random 40 of Sc TP mices are divided into 4 groups, by above-mentioned 1.1 dosage method, 5 treated animal every days, ig gave normal saline respectively, big low dose of stranguria with turbid discharge clearing capsule and LONGBISHU continuous 15 days, are cutd open after administration finishes and are got prostate and weigh, calculate its index, and observe morphological changes of various tissue components.
2, antiinflammatory action
2.1 influence to mice dimethylbenzene auricular concha inflammation
Get 40 of body weight 25g mices, be divided into 4 groups at random, 10 every group, the big low dose of difference ig stranguria with turbid discharge clearing capsule, Longbishu Jiaonang. and isometric(al) normal saline, continuously with 7 days, behind the 7th day administration 30min, organize mouse right ear in each and be coated with dimethylbenzene 0.05ml, left ear compares.After 15 minutes, put to death animal, take off with the card punch of diameter 6mm and respectively organize the auricle that mice ears symmetry locates and weigh, represent the swelling degree with left and right sides auricle weight difference.
2.2 to the bullate influence of rat granuloma
Get 40 of body weight 180g male rats, under etherization, the dry cotton ball of will sterilizing (each heavy 30mg) is imbedded rat both sides axillary fossa under the sterile working subcutaneous, after treating that animal is clear-headed, be divided into 4 groups at random, 10 every group, postoperative began ig administration (pressing the 10ml/kg body weight) same day, once a day, totally 7 days, put to death rat, and dissected and peel off granuloma induced by implantation of cotton pellets in the 8th day, 60 ℃ of bakings were weighed after 12 hours, and it is heavy to calculate granuloma.
3, analgesic effect
Get 40 of body weight 18g mices, male and female half and half are divided 4 groups at random, and medication is with 1.1, once a day, totally 3 times, behind the last medicine 1 hour, lumbar injection 0.6% glacial acetic acid 0.1ml/10g body weight immediately writes down the writhing response number of times in 20 minutes, calculates suppression ratio.
4, to the influence of normal rat urine
Get 40 of body weight 190g male rats, grouping, medication, dosage are put into metabolic cage with rat with 2.2 after the administration immediately, and 2 in every cage is collected 2h and 5h urine amount respectively.
Known positive control drug and selection foundation thereof
Longbishu Jiaonang. has: the effect of the kidney warming activating QI, clearing heat and freeing strangury, blood circulation promoting and blood stasis dispelling, removing obstruction for relieving pain, cure mainly: frequent micturition, urgent micturition, dark coloured urine, dysurea, urine thin due to the difficulty in urination of deficiency of kidney-QI, dampness and heat stasis, lower abdomen contracture pain, diseases such as soreness of the waist and knees, with the effect of stranguria with turbid discharge clearing capsule, cure mainly comparatively close, so select its positive contrast medicine.
Three, result of the test
1, to the influence of mice prostatic hyperplasia
1.1 preventive effect: medicine obviously alleviates (seeing Table 1) for the weight of prostate of treated animal
The preventive effect of table 1 pair prostatic hyperplasia
| Group (n) | Dosage (g/kg) | Prostate heavy (kg) | The prostate index |
| Blank group (10) | 0 | 38.02 | 1.17 |
| Model group (10) | 0 | 48.26** | 1.44** |
| LONGBISHU group (10) | 2.0 | 37.59* | 1.09* |
| Stranguria with turbid discharge is organized (10) clearly | 8.4 | 35.28* | 1.02* |
| Stranguria with turbid discharge is organized (10) clearly | 16.8 | 37.10* | 1.04* |
Annotate: compare with the blank group: * * P＜0.01, compare with model group: * P＜0.01.
In addition, the obvious hypertrophy of the visible model group prostate of microscopy, glandular epithelium forms most nipples, and the glandular epithelium hypertrophy is high column, and lumen of gland is narrowed down, and karyon is also seen increase; Administration group mice prostatic epithelium nipple obviously reduces, and glandular cell and normal phase are like be cube or the doll shape, and lumen of gland is also obviously roomy than model group, with the heavy dose of group of stranguria with turbid discharge clearing capsule for apparent.
1.2 therapeutical effect: medicine obviously alleviates (seeing Table 2) for the weight of prostate of treated animal
The therapeutical effect of table 2 pair mice prostatic hyperplasia
| Group (n) | Dosage (g/kg) | Prostate heavy (kg) | The prostate index |
| Blank group (10) | 0 | 36.93 | 1.11 |
| Model group (10) | 0 | 51.34** | 1.50** |
| LONGBISHU group (10) | 2.0 | 34.01* | 0.98* |
| Stranguria with turbid discharge is organized (10) clearly | 8.4 | 34.68* | 1.01* |
| Stranguria with turbid discharge is organized (10) clearly | 16.8 | 31.10* | 0.89* |
Annotate: compare with the blank group: * * P＜0.01, compare with model group: * P＜0.01.
In addition, microscopy shows that also prostatic glandular cell of administration group and interstitial proliferation all obviously alleviate than model group.
2, antiinflammatory action
2.1 the influence to mice dimethylbenzene auricular concha inflammation: the stranguria with turbid discharge clearing capsule obviously suppresses mice auricle swelling, the mice ear acute inflammation (seeing Table 3) due to effective anti-dimethylbenzene
The influence of table 3 pair mice dimethylbenzene auricular concha inflammation
| Group (n) | Dosage (g/kg) | Swelling degree (mg) |
| Matched group (10) | 0 | 17.6 |
| LONGBISHU group (10) | 2.0 | 11.54** |
| Stranguria with turbid discharge is organized (10) clearly | 8.4 | 12.04** |
| Stranguria with turbid discharge is organized (10) clearly | 16.8 | 11.16** |
Annotate: compare with the blank group: * * P＜0.01.
2.2 to the bullate influence of rat granuloma: the stranguria with turbid discharge clearing capsule has an obvious suppression effect (seeing Table 4) to rat granuloma is swollen
The influence of table 4 pair rat granuloma hypertrophy chronic inflammatory disease
| Group (n) | Dosage (g/kg) | Granulation heavy (mg) |
| Matched group (10) | 0 | 85.74 |
| LONGBISHU group (10) | 2.0 | 72.2* |
| Stranguria with turbid discharge is organized (10) clearly | 8.4 | 65.47** |
| Stranguria with turbid discharge is organized (10) clearly | 16.8 | 70.74* |
Annotate: compare with the blank group: * P＜0.05, * * P＜0.01.
3, analgesic effect: the stranguria with turbid discharge clearing capsule can obviously suppress the mouse writhing reaction (seeing Table 5) that acetic acid causes pain
Table 5 pair mice acetic acid causes the influence of pain
| Group (n) | Dosage (g/kg) | Turn round the body number | Suppression ratio (%) |
| Blank group (10) | 0 | 26.9 | 0 |
| LONGBISHU group (10) | 2.0 | 18.8** | 30.1 |
| Stranguria with turbid discharge is organized (10) clearly | 8.4 | 15.5** | 51.7 |
| Stranguria with turbid discharge is organized (10) clearly | 16.8 | 13.0** | 42.4 |
Annotate: compare with the blank group: * * P＜0.01.
4, to the influence of normal rat urine amount: the stranguria with turbid discharge clearing capsule can obviously increase the voided volume (seeing Table 6) of normal rat
The influence (ml/100g body weight) of table 6 pair normal rat urine amount
| Group (n) | Dosage (g/kg) | 2h | 5h |
| Blank group (10) | 0 | 26.9 | 0.115 |
| LONGBISHU group (10) | 1.0 | 18.8** | 0.311** |
| Stranguria with turbid discharge is organized (10) clearly | 4.2 | 15.5* | 0.580*** |
| Stranguria with turbid discharge is organized (10) clearly | 8.4 | 13.0* | 0.545* |
Annotate: compare with the blank group: * * P＜0.01, compare with the LONGBISHU group: * * * P＜0.05, * P＜0.01.
Conclusion (of pressure testing):
Medicine of the present invention--the Pharmacodynamic test of active extract of stranguria with turbid discharge clearing capsule shows: this product has prevention and therapeutical effect preferably to the mice prostatic hyperplasia due to the androlin, has tangible antiinflammatory, pain relieving and diuresis.
Test example 2: the toxicity test of stranguria with turbid discharge clearing capsule
1, materials and methods
1.1 animal: Kunming kind white mice, body weight 20g, male and female half and half.
1.2 medicine: the stranguria with turbid discharge clearing capsule, make 30% suspension.
1.3 method: get 40 of mices, be divided into test group and matched group at random, every group 20, the former irritates stomach and awards stranguria with turbid discharge clearing capsule solution, each 0.4ml/10g, every day 3 times is every 8 hours 1 time, give medicinal liquid 1,2ml/10g (Cmax and maximum volume) in 1 day altogether, being total to dosage in promptly 1 day is 36g/kg.d.Matched group then to award the equal-volume normal saline with method, reaches the general variation and the survival condition of observing animal a week respectively after the drug withdrawal in 24 hours behind medicine, and compare its main organs: the mode of appearance of the heart, liver, spleen, lung, kidney with the normal control group.
2, result
The test group mice does not see any unusual after administration in 24 hours and in the week, do not have dead yet.Animals received dosage is equivalent to 428.6 times (seeing Table 7) of clinical medicine dose.
Table 7 animal acute toxicity test result
| Group | Number of animals (only) | Dosage (g/kg) | Death toll (only) | Ingest several unusually (only) | Visceral organ injury number (only) | Suitable clinical application multiple |
| Matched group | 20 | 0 | 0 | 0 | 0 | 0 |
| Test group | 20 | 36 | 0 | 0 | 0 | 428.6 |
3, conclusion
Show that through animal acute toxicity test this product is irritated stomach with Cmax, maximum volume to animal, do not see any tangible toxicity, show the stranguria with turbid discharge clearing capsule for not have cytotoxic drug substantially, safety is good.
Test example 3: the clinical observation of Drug therapy prostatosis of the present invention
1, physical data: from out-patient's 110 routine case histories, get 55 examples and organize, and selection medical history, the state of an illness, year order and suitable patient's 55 examples of former Therapeutic Method are matched group as treatment.
2, diagnostic criteria: according to the DIAGNOSIS OF CHRONIC PROSTATITIS standard of " combination of Chinese and Western medicine diagnoses and treatment " formulation.
3, Therapeutic Method:
3.1 the treatment group is taken ' stranguria with turbid discharge clearing capsule ', every day 3 times, and each 4, warm water delivery service, 30 days is a course of treatment, checks after taking two courses of treatment continuously: prostatic fluid microscopy and measure SIgA content in the prostatic fluid.
3.2 matched group is taken ' qian lie tong yu jiao nang ' (Zhuhai starlight pharmacy), every day 3 times, each 5,30 days is a course of treatment, checks after taking two courses of treatment continuously: prostatic fluid microscopy and measure SIgA content in the prostatic fluid.
3.3 observation item and standards of grading:
(1) pain symptom, the symptom score of urinating way, the order of severity of pressing prostatitis is with reference to the SSI standard, divide accumulation from 0-50 respectively: asymptomatic note 0 minute, symptom score 1-10 minute mark 1 minute, symptom score 11-20 minute mark 2 minutes, symptom score 21-30 minute mark 3 minutes, symptom score 31-40 minute mark 4 minutes, symptom score 41-50 minute mark 5 minutes.
(2) the unusual methods of marking of sexual function: sex time was normal greater than 2 minutes, remembered 0 fen, and the sex time less than 2 minutes was slight, remembered 1 fen, and erection is not hard to be moderate, remembers 2 fens, and the complete anorthosis of penis is serious, remembers 3 fens.
(3) the unusual methods of marking of prostate touch, press prostate tenderness, scleroma, the soft scoring firmly in various degree of matter: no abnormal note 0 minute, slightly remember 1 fen, moderate note 2 minutes, severe note 3 minutes.
3.4 lab testing and scoring system
Examination of prostatic fluid is kept the score: lecithin (antiinflammatory) note 1 minute, and (+) note 2 minutes, (++) note 3 minutes, (+++) remember 4 fens, (++ ++) remember 5 fens; Leukocyte (or ±) remember 5 fens, (+) note 4 minutes, (++) note 3 sides, (+++) remember 2 fens, (++ ++) remember 1 fen.
After the prostatic fluid spectroscopy, will remain specimen and place-70 ℃ of freezing preservations, survey SIgA content with immunodiffusion method.
4, criterion of therapeutical effect and therapeutic outcome
4.1 criterion of therapeutical effect is carried out according to the criterion of therapeutical effect of ' chronic prostatitis ' in " combination of Chinese and Western medicine diagnoses and treatment ".
4.2 therapeutic outcome
4.2.1 treatment group and matched group clinical efficacy are relatively:
Treatment group and matched group clinical cure rate, obvious effective rate, total effective rate compare, and difference has highly significant meaning (P＜0.01), and treatment group curative effect is better than seeing Table 8 to right group.
Table 8 treatment group and matched group clinical efficacy are relatively
| Group | N | Clinical cure | Produce effects | Effectively | Invalid | Total effective rate (%) |
| The treatment group | 55 | 27(49.09) | 21(38.18) | 5(9.09) | 2(3.63) | 96.37 |
| Matched group | 55 | 10(18.18) | 10(18.18) | 24(43.63) | 11(20.0) | 80.00 |
4.2.2 the cardinal symptom integration relatively before and after treatment group and the treatment of control group: cardinal symptom, sign are relatively before and after treatment group and the treatment of control group, difference has highly significant meaning (P＜0.05-0.01), the treatment group is better than matched group aspect symptom, the sign improving, and sees Table 9.
The cardinal symptom integration relatively before and after table 9 treatment
| Project | Treatment group (n=55) | Matched group (n=55) | ||
| Before the treatment | After the treatment | Before the treatment | After the treatment | |
| Pain | 3.31±1.24 | 0.15±0.42 | 3.04±1.2 | 0.91±1.21 |
| The symptom of urinating | 2.96±1.21 | 0.38±0.76 | 2.91±1.13 | 1.68±1.16 |
| Sexual function is unusual | 1.82±0.85 | 1.30±0.97 | 1.81±0.84 | 1.42±1.10 |
| The prostate touch is unusual | 1.72±0.96 | 0.70±0.43 | 1.70±0.82 | 1.15±0.64 |
4.2.3 prostatic fluid microscopy integration changes relatively before and after treatment group and the treatment of control group: after the treatment, the treatment group increases than matched group ovum phosphoric acid lipophore, and WBC reduces, through check, difference has highly significant meaning (P＜0.01), and treatment group curative effect is better than seeing Table 10 to right group.
Prostatic fluid microscopy integration changes relatively before and after table 10 treatment
| Project | Treatment group (n=55) | Matched group (n=55) | ||
| Before the treatment | After the treatment | Before the treatment | After the treatment | |
| Ovum phosphoric acid lipophore | 2.01±1.16 | 3.56±1.12 | 2.12±1.04 | 2.42±1.06 |
| Leukocyte | 1.86±1.24 | 4.08±1.24 | 1.71±1.20 | 3.64±1.20 |
4.2.4 the variation of SIgA content relatively in treatment group and the treatment of control group front and back prostatic fluid: after the treatment, the treatment group obviously reduces (P＜0.01) than SIgA content in the matched group prostatic fluid.Illustrate that the reagentia of treatment group adjusting prostate local immunity is better than matched group, sees Table 11.
The variation of SigA content relatively in the prostatic fluid of table 11 treatment front and back
| Group | n | Before the treatment | After the treatment |
| The treatment group | 55 | 115.21±56.34 | 40.26±18.14 |
| Matched group | 55 | 98.86±63.12 | 74.48±31.62 |
In a word, with " stranguria with turbid discharge clearing capsule " treatment 55 examples, the result cures 27 examples, produce effects 21 examples, and 5 examples that take a turn for the better, invalid 2 examples, cure rate is 49.1%, and obvious effective rate is 87.27%, and total effective rate is 96.37%.
Come further to set forth the proportioning and the preparation method of medicine of the present invention by the following examples.
Embodiment 1
A kind of Chinese medicinal capsule (stranguria with turbid discharge clearing capsule) for the treatment of prostatosis, the weight proportion of its raw material is: Rhizoma Smilacis Glabrae 30 grams, Cortex Phellodendri 10 grams, the Radix Linderae 10 grams, Fructus Alpiniae Oxyphyllae 10 grams, the Rhizoma Atractylodis Macrocephalae 10 grams, Bi 15 grams, Radix Cyathulae 10 grams, Rhizoma Acori Graminei 10 grams, Radix Ginseng 8 grams, Herba Hedyotidis Diffusae 30 grams, Pheretima 10 grams, Fructus Cnidii 10 grams, Radix Glycyrrhizae uralensis 6 grams.
The compound method of the Chinese medicinal capsule (stranguria with turbid discharge clearing capsule) of treatment prostatosis, its step is as follows:
(1) Rhizoma Smilacis Glabrae by weight ratio, Cortex Phellodendri, the Radix Linderae, Fructus Alpiniae Oxyphyllae, the Rhizoma Atractylodis Macrocephalae, Bi , Radix Cyathulae, Rhizoma Acori Graminei, Herba Hedyotidis Diffusae, Pheretima, Radix Glycyrrhizae uralensis, Fructus Cnidii 12 flavor Chinese medicines are soaked;
(2) decoct secondary;
(3) collecting decoction, filtration;
(4) filtrate to be concentrated into relative density be 1.35-1.40;
(5) Chinese medicine Radix Ginseng powder essence by weight ratio, sieve;
(6) with concentrated thick paste and the mixing of Radix Ginseng fine powder such as above-mentioned Rhizoma Smilacis Glabraes;
(7) drying;
(8) pulverize, sieve;
(9) branch is encapsulated.
Claims (2)
1, a kind of Chinese medicinal capsule for the treatment of prostatosis is characterized in that being made by following materials of weight proportions: Rhizoma Smilacis Glabrae 30 grams, Cortex Phellodendri 10 grams, the Radix Linderae 10 grams, Fructus Alpiniae Oxyphyllae 10 grams, the Rhizoma Atractylodis Macrocephalae 10 grams, Bi 10 grams, Rhizoma Acori Graminei 10 grams, Radix Ginseng 8 grams, Herba Hedyotidis Diffusae 30 grams, Pheretima 10 grams, Radix Cyathulae 10 grams, Fructus Cnidii 10 grams, Radix Glycyrrhizae uralensis 6 grams.
2, according to the compound method of the Chinese medicinal capsule of the described treatment prostatosis of claim 1, it is characterized in that: its step is as follows:
(1) Rhizoma Smilacis Glabrae by weight ratio, Cortex Phellodendri, the Radix Linderae, Fructus Alpiniae Oxyphyllae, the Rhizoma Atractylodis Macrocephalae, Rhizoma Dioscoreae Septemlobae, Rhizoma Acori Graminei, Herba Hedyotidis Diffusae, Pheretima, Radix Cyathulae, Fructus Cnidii, Radix Glycyrrhizae uralensis 12 flavor Chinese medicines are soaked;
(2) decoct secondary;
(3) collecting decoction, filtration;
(4) filtrate to be concentrated into relative density be 1.35～1.40;
(5) Chinese medicine Radix Ginseng powder essence by weight ratio, sieve;
(6) 12 flavor Chinese medicines with step (1)～(4) preparation concentrate thick paste and the mixing of step (5) preparation Radix Ginseng fine powder;
(7) drying;
(8) pulverize, sieve;
(9) branch is encapsulated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03155282 CN1197614C (en) | 2003-08-28 | 2003-08-28 | Chinese medicine cap sule for treating prostatic disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03155282 CN1197614C (en) | 2003-08-28 | 2003-08-28 | Chinese medicine cap sule for treating prostatic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1488394A CN1488394A (en) | 2004-04-14 |
| CN1197614C true CN1197614C (en) | 2005-04-20 |
Family
ID=34156835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03155282 Expired - Fee Related CN1197614C (en) | 2003-08-28 | 2003-08-28 | Chinese medicine cap sule for treating prostatic disorders |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1197614C (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100413529C (en) * | 2004-12-07 | 2008-08-27 | 崔小明 | Chinese medicinal composition for treating prostatitis and its preparation method |
| CN101703591B (en) * | 2009-12-01 | 2011-09-28 | 张坤镛 | Medicament for effectively treating prostate diseases |
| CN101843872B (en) * | 2010-05-25 | 2011-07-06 | 泰一和浦（北京）中医药研究院有限公司 | Chinese medicinal composition for treating turbid urine and preparation method thereof |
| CN102526584B (en) * | 2012-03-27 | 2013-09-11 | 郑州密丽药业有限公司 | Chinese medicine for treating prostate disease and preparation method thereof |
| CN103611031B (en) * | 2013-11-13 | 2015-09-16 | 李跃 | Be used for the treatment of the plaster of prostatic hyperplasia |
| CN105148051A (en) * | 2015-07-25 | 2015-12-16 | 王军 | Traditional Chinese medicinal composition for treating chronic prostatitis |
| CN105056028A (en) * | 2015-08-06 | 2015-11-18 | 苏州神林堂中医药研究所 | Drug for treatment of chronic prostatitis |
-
2003
- 2003-08-28 CN CN 03155282 patent/CN1197614C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1488394A (en) | 2004-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103751310B (en) | A kind of traditional Chinese medicine for external application and its preparation method treating fascitis | |
| CN1861163A (en) | Traditional Chinese medicine composition for treating kidney-yang deficiency and deficiency of vital energy and blood, its prepn. process | |
| CN102058715B (en) | Chinese medicine preparation for treating chronic prostatitis and preparation method thereof | |
| CN101066326A (en) | Chinese medicine for treating kidney deficiency and its prepn | |
| CN1197614C (en) | Chinese medicine cap sule for treating prostatic disorders | |
| CN1927322A (en) | Liposoluble traditional medicine bougie for treating acute and chronic prostatitis, and manufacturing technique thereof | |
| CN101695527B (en) | Toxin-expelling intestine-moistening Chinese medicinal preparation and preparation method thereof | |
| CN1251748C (en) | Lotion for treating gynecological disease and its preparation process | |
| CN1078081C (en) | Medicine for treating osteoproliferation, rheumatism and rheumatoid arthritis, and preparing method thereof | |
| CN1234407C (en) | Medicine for treating chronic prostatitis and its preparing method | |
| CN103860894B (en) | A kind of medicine for the treatment of chronic prostatitis | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN1435247A (en) | Chinese medicine preparation for treating lithiasis in urinary system and urethral infection, and preparing method thereof | |
| CN1899490A (en) | Liniment for treating acute and chronic soft tissue injury of qi stagnation and blood stasis and its preparing method | |
| CN101249236B (en) | Chinese and western medicine combined preparations for curing epileptic | |
| CN1251751C (en) | Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis | |
| CN1686272A (en) | Medicine for treating chronic prostatitis and its preparation method | |
| CN1772239A (en) | Chinese medicine prepn for treating vaginitis and cervicitis | |
| CN1634235A (en) | Medicine for treating colitis | |
| CN101053624A (en) | Traditional Chinese medicinal for treating prostatic hyperplasia and chronic prostatitis and its preparation process | |
| CN1301125C (en) | Medicine for treating gastrointestinal tract disease | |
| CN1840049A (en) | Medicine for treating diabetic nephropathy | |
| CN104491312A (en) | Use of tradtional Chinese medicine preparation in preparing medicines for treating prostatitis and prostatauxe | |
| CN1824077A (en) | Chinese medicinal liquid capsule for treating gynecopathy and its preparation method | |
| CN1438026A (en) | Medicine for treating venereal disease and urinary system disease and production method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050420 Termination date: 20100828 |